Potential therapeutic GSK-3β inhibitor 9-ING-41 is active in combination with venetoclax in double-hit lymphoma (DHL)
The demonstrated single-agent efficacy and combination synergy with venetoclax support the potential of 9-ING-41 as a novel therapeutic strategy for DHL. These findings provide a proof-of-concept that may serve as a basis for future preclinical investigations in DHL.
Authors
- Haohao Lei (ORCID: https://orcid.org/0009-0005-1606-8100)
- Xutao Guo (ORCID: https://orcid.org/0000-0001-6191-2204)
- Haiqing Zheng (ORCID: https://orcid.org/0009-0005-8141-3003)
- Xiaolei Wei (ORCID: https://orcid.org/0000-0002-4271-9588)
- Pengcheng Shi
- Yunxia Zhang (ORCID: https://orcid.org/0009-0008-2943-4722)
Institutions
- National Clinical Research Center for Digestive Diseases (CN)
- Nanfang Hospital (CN)
- New Huadu Business School (CN)
- Southern Medical University (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Cancer Biology & Therapy
- Published
- 2025-11-11
- DOI
- https://doi.org/10.1080/15384047.2025.2581831
- Primary Topic
- Wnt/β-catenin signaling in development and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00